Empagliflozin
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (7) | US (FDA) | JARDIANCE | — | 2015-06-26 – 2023-09-21 | fda.gov ↗ |
| Approved | US (FDA) | JARDIANCE | — | 2014-08-01 | fda.gov ↗ |
| Approved | EU (EMA) | Jardiance | — | 2014-05-22 | europa.eu ↗ |
Trials 350 · started per year
Also used as a comparator or background therapy in 141 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07055282 Comparator | Nov 2025 → Nov 2027 expected | urolithiasis | University of Chicago | Recruiting | No outcome recorded |
| Phase 0 | NCT06609356 Comparator | Jul 2025 → Jul 2027 expected | maturity-onset diabetes of the young type 2, type 1 diabetes mellitus | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT04203927 Comparator | Feb 2020 → Oct 2023 | type 2 diabetes mellitus | University of Virginia | Unknown | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07102719 Comparator | Sep → Oct 2025 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06889350 Comparator | Mar → Apr 2025 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06339788 Comparator | May → Jun 2024 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01328184 Comparator | Apr → Jul 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01276301 Comparator | Jan → Feb 2011 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05972564 Comparator | Sep 2023 → Sep 2026 expected | metabolic syndrome X, obesity disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT07304817 Background | May 2026 → Feb 2028 expected | chronic kidney disease, heart failure | University Medical Center Groningen | Recruiting | No outcome recorded |
| Phase 2 | NCT07372040 Comparator | Feb 2026 → Feb 2027 expected | heart failure | Tanta University | Recruiting | No outcome recorded |
| Phase 2 | NCT06926660 Background | Jul 2025 → Aug 2026 overdue | chronic kidney disease | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06992440 Comparator | Jun 2025 → Jul 2030 expected | pulmonary arterial hypertension | The Cleveland Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06655480 Background | Mar 2025 → Dec 2027 expected | intrinsic cardiomyopathy, symptomatic heart failure | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Recruiting | No outcome recorded |
| Phase 2 | NCT07482020 Comparator | Mar 2025 → Dec 2026 expected | hypertensive disorder, paroxysmal atrial fibrillation | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06762314 Comparator | Jan 2025 → Sep 2027 expected | diabetes mellitus | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 2 | NCT06012266 Comparator | Aug 2024 → Aug 2025 | heart failure | Centre Hospitalier Universitaire Vaudois | Unknown | No outcome recorded |
| Phase 2 | NCT06483074 Comparator | Jul 2024 → Jul 2026 overdue | end stage renal failure | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT06147271 Comparator | Nov 2023 → Feb 2025 | heart failure, transplant rejection | Federal University of Ceará | Unknown | No outcome recorded |
| Phase 2 | NCT05726032 Comparator | Sep 2023 → Jun 2026 overdue | cirrhosis of liver, liver failure | Yale University | Recruiting | No outcome recorded |
| Phase 2 | NCT05638880 Background | Dec 2022 → Dec 2025 | diabetic kidney disease | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 2 | NCT04906213 Comparator | Jul 2022 → Jan 2026 | type 2 diabetes mellitus | Duke University | Terminated | No outcome recorded |
| Phase 2 | NCT05138575 Comparator | Jan 2022 → May 2027 expected | diastolic heart failure | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 2 | NCT05042973 Comparator | Sep 2021 → Jan 2025 | heart failure, obesity disorder | Jacob Moller | Completed | No outcome recorded |
| Phase 2 | NCT05084235 Comparator | Sep 2021 → Jan 2025 | heart failure, obesity disorder | Jacob Moller | Completed | No outcome recorded |
| Phase 2 | NCT04911660 Comparator | Aug 2021 → Mar 2023 | urolithiasis | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT04662866 Comparator | Feb 2021 → Dec 2022 | glucose intolerance | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04049045 Comparator | Sep 2019 → May 2021 | heart failure | Christian Schulze | Completed | No outcome recorded |
| Phase 2 | NCT03462069 Comparator | Mar 2018 → Apr 2019 | diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT03200860 Comparator | Dec 2017 → Sep 2019 | congestive heart failure | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT03152552 Comparator | Jul 2017 → Jun 2018 | diabetes mellitus, noninsulin-dependent, 2 | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03128528 Comparator | Jul 2017 → Jan 2020 | heart failure | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 2 | NCT03198585 Comparator | Jun 2017 → Dec 2019 | symptomatic heart failure | Morten Schou | Completed | No outcome recorded |
| Phase 2 | NCT03227484 Comparator | Jun 2017 → Oct 2019 | prediabetes syndrome | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT03093103 Comparator | Mar 2017 → Dec 2018 | — | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07591077 Comparator | Nov 2024 → Nov 2025 | diabetic kidney disease, type 1 diabetes mellitus | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT06149793 Comparator | Jan 2024 → Jun 2025 overdue | cystic fibrosis, cystic fibrosis-related diabetes | University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03202667 Comparator | Dec 2017 → Aug 2021 | inappropriate ADH syndrome | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2/3 | NCT02874807 Comparator | Sep 2016 → Dec 2018 | inappropriate ADH syndrome | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 2/3 | NCT02729766 Comparator | Mar → Jul 2016 | inappropriate ADH syndrome | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 337 trials | ||||||
| Phase 3 | NCT07038356 Comparator | Dec 2025 → Apr 2026 overdue | heart failure | Christian Schulze | Recruiting | No outcome recorded |
| Phase 3 | NCT07064473 Background | Jul 2025 → Dec 2029 expected | hypertensive disorder, type 2 diabetes mellitus | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT07093476 Comparator | Jul 2025 → Dec 2026 expected | type 2 diabetes mellitus | Celltrion | Recruiting | No outcome recorded |
| Phase 3 | NCT06935370 Background | May 2025 → Feb 2029 expected | heart failure | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06955260 Comparator | May 2025 → Dec 2027 expected | congenital heart disease | Subodh Verma | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04670666 Comparator | Nov 2024 → Jul 2026 overdue | type 2 diabetes mellitus | EMS | Recruiting | No outcome recorded |
| Phase 3 | NCT05028140 Comparator | Oct 2024 → Jul 2026 overdue | type 2 diabetes mellitus | EMS | Recruiting | No outcome recorded |
| Phase 3 | NCT06531824 Background | Aug 2024 → Aug 2028 expected | chronic kidney disease | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06571591 Comparator | Aug 2024 → Apr 2026 | type 2 diabetes mellitus | Celltrion | Completed | No outcome recorded |
| Phase 3 | NCT06424288 Background | Jun 2024 → May 2028 expected | heart failure | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT06952231 Comparator | May → Dec 2024 | diabetes mellitus | University of Lahore | Completed | No outcome recorded |
| Phase 3 | NCT04602754 Comparator | Dec 2023 → May 2026 overdue | type 2 diabetes mellitus | EMS | Recruiting | No outcome recorded |
| Phase 3 | NCT05271162 Comparator | Sep 2023 → Jan 2028 expected | chemotherapy-induced toxicity | Maria Sklodowska-Curie National Research Institute of Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04970108 Comparator | Aug 2023 → Jan 2025 | hypertensive disorder, type 2 diabetes mellitus | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT05669742 Comparator | May 2023 → Jun 2026 overdue | — | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT04603508 Comparator | Mar 2023 → Apr 2025 | hyperlipidemia, type 2 diabetes mellitus | EMS | Unknown | No outcome recorded |
| Phase 3 | NCT05605158 Comparator | Nov 2022 → May 2023 | metabolic dysfunction-associated steatohepatitis | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05444153 Comparator | Oct 2022 → Oct 2024 | type 2 diabetes mellitus | Novo Nordisk A/S | Withdrawn | No outcome recorded |
| Phase 3 | NCT05144360 Comparator | Aug 2022 → Jul 2024 | hypertensive disorder, type 2 diabetes mellitus | EMS | Withdrawn | No outcome recorded |
| Phase 3 | NCT05417880 Comparator | Aug 2022 → Feb 2023 | type 2 diabetes mellitus | Scotmann Pharmaceuticals | Unknown | No outcome recorded |
| Phase 3 | NCT05364190 Comparator | Jun 2022 → Dec 2023 | diabetes mellitus, heart failure | October 6 University | Completed | No outcome recorded |
| Phase 3 | NCT05182658 Comparator | Jun 2022 → Sep 2026 expected | heart failure, hypertrophic cardiomyopathy | National Institute of Cardiology, Warsaw, Poland | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05776043 Comparator | Mar 2022 → Sep 2024 | heart failure | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 3 | NCT04345796 Comparator | Feb 2021 → Jun 2024 | tricuspid valve insufficiency | Asan Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT05283057 Comparator | Feb 2020 → Sep 2021 | glomerulonephritis, proteinuria | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03979352 Comparator | Aug 2019 → Aug 2021 | type 1 diabetes mellitus | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03351478 Comparator | Nov 2017 → May 2019 | type 2 diabetes mellitus | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03173963 Comparator | May 2017 → Feb 2020 | diabetic kidney disease, type 2 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Withdrawn | No outcome recorded |
| Phase 3 | NCT03087773 Comparator | May 2017 → May 2022 | acute myocardial infarction | Medical University of Graz | Completed | No outcome recorded |
| Phase 3 | NCT02863328 Comparator | Aug 2016 → Aug 2017 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT02752113 Comparator | Apr 2016 → Nov 2018 | type 2 diabetes mellitus | Institute for Pharmacology and Preventive Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02597049 Background | Nov 2015 → Feb 2017 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT02489968 Background | May 2015 → Nov 2016 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02471963 Comparator | Dec 2014 → Nov 2015 | type 2 diabetes mellitus | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 3 | NCT01778049 Background | Jan 2013 → Mar 2015 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01422876 Comparator | Aug 2011 → Sep 2013 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 449 trials | ||||||
| Phase 4 | NCT07228195 Comparator | Jul 2026 → Dec 2028 expected | diabetes mellitus | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07547878 Comparator | Apr 2026 → Mar 2029 expected | chronic kidney disease, type 2 diabetes mellitus | Baylor Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07322237 Comparator | Apr 2026 → Jan 2029 expected | cardiovascular-kidney-metabolic syndrome, cirrhosis of liver, cirrhotic cardiomyopathy | Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting | No outcome recorded |
| Phase 4 | NCT07074418 Comparator | Apr 2026 → Dec 2027 expected | chronic kidney disease | Centre Hospitalier Universitaire de Nice | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07452913 Comparator | Jan → Mar 2026 overdue | type 2 diabetes mellitus | Bahria University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07180745 Comparator | Nov 2025 → Feb 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Badr University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07292909 Comparator | Sep 2025 → Jun 2027 expected | coronary artery disorder | Hotel Dieu de France Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07155694 Comparator | Sep 2025 → Jul 2027 expected | diabetic kidney disease | Washington D.C. Veterans Affairs Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06933355 Comparator | Mar 2025 → Apr 2026 overdue | disease related to solid organ transplantation | Odense University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06759922 Comparator | Jan → Mar 2025 | type 2 diabetes mellitus | Bahria University | Completed | No outcome recorded |
| Phase 4 | NCT07325435 Comparator | Dec 2024 → Dec 2027 expected | type 2 diabetes mellitus | MaryAnn Banerji | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07531108 Comparator | Nov 2024 → Nov 2025 | type 2 diabetes mellitus | Hawler Medical University | Completed | No outcome recorded |
| Phase 4 | NCT06641128 Comparator | Oct 2024 → Mar 2025 overdue | methotrexate toxicity, rheumatoid arthritis | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06613854 Comparator | Oct 2024 → Sep 2027 expected | type 2 diabetes mellitus | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06410352 Comparator | Mar 2024 → Sep 2025 overdue | metabolic syndrome X | University Medical Center, Kazakhstan | Recruiting | No outcome recorded |
| Phase 4 | NCT06171802 Comparator | Feb 2024 → May 2026 | aortic valve stenosis | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT06110130 Comparator | Feb 2024 → Dec 2027 expected | chronic kidney disease | Washington D.C. Veterans Affairs Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06642623 Comparator | Jan 2024 → Sep 2029 expected | cardiovascular disorder, kidney disorder, type 2 diabetes mellitus | Yonsei University | Recruiting | No outcome recorded |
| Phase 4 | NCT05989503 Comparator | Aug 2023 → Jul 2025 | symptomatic heart failure | University of Porto | Completed | No outcome recorded |
| Phase 4 | NCT07363707 Comparator | May → Aug 2023 | NAFLD1 | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT07247656 Comparator | Dec 2022 → Mar 2023 | type 2 diabetes mellitus | Bahria University | Completed | No outcome recorded |
| Phase 4 | NCT05129722 Comparator | Oct 2022 → May 2024 | diastolic heart failure | The George Institute | Terminated | No outcome recorded |
| Phase 4 | NCT05390892 Comparator | Sep 2022 → Mar 2029 expected | atherosclerotic cardiovascular disease, type 2 diabetes mellitus | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05147090 Comparator | Jan 2022 → Dec 2027 expected | chronic hepatitis B virus infection, cirrhosis of liver, fibrotic liver disease, metabolic dysfunction-associated steatotic liver disease | The University of Hong Kong | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05857085 Comparator | Dec 2021 → Mar 2022 | type 1 diabetes mellitus | General and Teaching Hospital Celje | Completed | No outcome recorded |
| Phase 4 | NCT05200793 Comparator | Dec 2021 → Jul 2022 | polycystic ovary syndrome | Alexandria University | Unknown | No outcome recorded |
| Phase 4 | NCT04976283 Comparator | Sep 2021 → May 2023 | NAFLD1, metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Getz Pharma | Unknown | No outcome recorded |
| Phase 4 | NCT04583813 Comparator | Sep 2021 → Jan 2024 | atrial fibrillation, diabetes mellitus, heart failure, obesity disorder | Miulli General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04796428 Comparator | Jun 2021 → Dec 2023 | type 2 diabetes mellitus | Center for Outcomes Research and Clinical Epidemiology, Italy | Unknown | No outcome recorded |
| Phase 4 | NCT04461041 Comparator | Apr 2021 → Jul 2022 | cardiovascular disorder | Unity Health Toronto | Completed | No outcome recorded |
| Phase 4 | NCT04523064 Comparator | Sep 2020 → Jan 2024 | acute kidney injury, coronary artery disorder, type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04215445 Comparator | Dec 2019 → May 2020 | chronic kidney disease, diabetes mellitus, diabetic retinopathy | National University of Malaysia | Unknown | No outcome recorded |
| Phase 4 | NCT04196231 Comparator | Nov 2019 → Sep 2020 | type 2 diabetes mellitus | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 4 | NCT04061200 Comparator | Nov 2019 → Jul 2021 | diabetic kidney disease | Steno Diabetes Center Copenhagen | Unknown | No outcome recorded |
| Phase 4 | NCT04013581 Comparator | Aug 2019 → May 2020 | type 2 diabetes mellitus | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT03912909 Comparator | Aug 2018 → Mar 2024 | metabolic syndrome X, obesity disorder, type 2 diabetes mellitus | Royal Perth Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03642184 Comparator | Jul 2018 → Jan 2019 | disease related to solid organ transplantation | RenJi Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT03485092 Comparator | Mar 2018 → Mar 2020 | diabetes mellitus, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| Phase 4 | NCT03639545 Comparator | Mar → Dec 2018 | arterial disorder, type 1 diabetes mellitus | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| Phase 4 | NCT03271879 Comparator | Feb 2018 → Sep 2019 | cardiac rhythm disease, diabetes mellitus, heart failure | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 4 | NCT03226457 Comparator | Dec 2017 → Dec 2018 | heart failure, type 2 diabetes mellitus | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT02768220 Comparator | Dec 2017 → Aug 2018 | diabetes mellitus | Northwell Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT03030222 Comparator | Jul 2017 → Mar 2020 | heart failure | Saint Luke's Health System | Completed | No outcome recorded |
| Phase 4 | NCT02998970 Comparator | Jan 2017 → Sep 2018 | cardiovascular disorder, type 2 diabetes mellitus | Unity Health Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT03157414 Comparator | Nov 2016 → Jun 2018 | diabetes mellitus, impaired renal function disease | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01001962 Comparator | Jan 2016 → Jan 2019 | hypertensive disorder, type 2 diabetes mellitus | Aristotle University Of Thessaloniki | Unknown | No outcome recorded |
| Phase 4 | NCT02528019 Comparator | Aug 2015 → Aug 2017 | — | Kurume University | Unknown | No outcome recorded |
| Phase 4 | NCT02041234 Comparator | Feb 2014 → Dec 2020 | type 2 diabetes mellitus | Khoo Teck Puat Hospital | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07331220 Background | Dec 2026 → Dec 2028 expected | diastolic heart failure | Nanjing First Hospital, Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07694596 Background | Jun 2026 → Apr 2028 expected | cognitive disorder, type 2 diabetes mellitus | University of Primorska | Active not recruiting | No outcome recorded |
| — | NCT07391267 Background | Feb 2026 → Dec 2028 expected | chronic kidney disease, metabolic dysfunction-associated steatotic liver disease | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT07335900 Background | Dec 2025 → Dec 2026 expected | aortic valve stenosis | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06930092 Comparator | Aug 2025 → Apr 2028 expected | cardiomyopathy | Seoul National University Hospital | Recruiting | No outcome recorded |
| — | NCT07379788 Comparator | Jan 2025 → Feb 2026 | heart failure | Rehab Werida | Completed | No outcome recorded |
| — | NCT07303556 Background | Dec 2024 → Jul 2025 overdue | heart failure, hypertensive disorder, type 2 diabetes mellitus | Nazarbayev University | Active not recruiting | No outcome recorded |
| — | NCT05417646 Comparator | Jun 2022 → Jun 2023 | maturity-onset diabetes of the young type 3, type 2 diabetes mellitus | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| — | NCT05359341 Comparator | Sep 2020 → Sep 2021 | type 2 diabetes mellitus | Sadat City University | Completed | No outcome recorded |
| — | NCT04061473 Comparator | Apr → Aug 2019 | post-surgical hypoinsulinemia | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT03591991 Comparator | Oct 2018 → Jan 2019 | acute myocardial infarction | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT03200782 Comparator | May 2017 → Sep 2018 | dumping syndrome, hypoglycemia | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| — | NCT02846233 Comparator | Aug 2016 → Dec 2018 | type 2 diabetes mellitus | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT02792400 Comparator | May → Aug 2016 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT02686476 Comparator | Mar 2016 → Sep 2017 | NAFLD1 | Medanta, The Medicity, India | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-05-29 | Novo Nordisk A/S | Oral semaglutid viser større forbedring i langtidsblodsukker sammenlignet med empagliflozin i PIONEER 2-studiet novonordisk.com ↗ |
| 2018-05-29 | Novo Nordisk A/S | Oral semaglutide shows superior improvement in HbA1c vs empagliflozin in the PIONEER 2 trial novonordisk.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 503 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Empagliflozin | “Subjects not receiving antidiabetes therapy for ≥12 weeks were randomized to empagliflozin 25 mg/linagliptin 5 mg (n = 137), empagliflozin 10 mg/linagliptin 5 mg (n = 136),...” PMID 25633662 ↗ Jan 2015460“Participants randomized to the intervention group will receive empagliflozin (10 mg once daily, with optional titration to 25 mg according to clinical judgement and...” NCT07694596 ↗ “Patients with acute decompensated HF will be open-label randomly assigned to be treated with or without SGLT2 inhibitors (either empagliflozin 10 mg once daily or dapagliflozin...” NCT06142474 ↗ “BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients...” PMID 26378978 ↗ Sep 2015 “Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% \<HbA1c ≤ 10%) with...” NCT04013581 ↗ “Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With...” NCT01301742 ↗ “The specific agent (e.g., dapagliflozin or empagliflozin) and dose will be selected based on safety data and clinical guidelines applicable to patients with end-stage renal...” NCT06929169 ↗ “Sequential discontinuation of angiotensin receptor-neprilysin inhibitor (ARNI; e.g., sacubitril/valsartan) and sodium-glucose cotransporter-2 inhibitor (SGLT2i; e.g.,...” NCT07631156 ↗ “The purpose of our study is to see if a small dose of empagliflozin (2.5 mg and 5 mg) is enough to help those who cannot achieve adequate glucose control on a closed-loop...” NCT04450563 ↗ “Patients with inadequate glycaemic control despite stable-dose metformin received open-label empagliflozin 10 mg (study 1) or 25 mg (study 2) as add-on therapy for 16 weeks.” PMID 27762093 ↗ Nov 2016 “Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.” PMID 24948511 ↗ Jun 2014 “This relative bioavailability study compared a fixed-dose combination (FDC) tablet of empagliflozin 25 mg/linagliptin 5 mg with the corresponding individual components.” PMID 28290274 ↗ Apr 2017 “Empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, ameliorates hyperglycemia in patients with type 2 diabetes (T2D) by inducing sustained glucosuria.” PMID 29488164 ↗ Feb 2018 “Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers” NCT01284621 ↗ “Intervention: Dapagliflozine 10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment.” NCT04127084 ↗ “All patients will be started on an SGLT2i (Empagliflozin or Dapagliflozin) and a betablocker (Metoprolol, Bisoprolol or Carvedilol) right after study inclusion.” NCT05637853 ↗ “Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors” NCT06449235 ↗ “Empagliflozin is a potent, selective inhibitor of sodium glucose cotransporter 2 in development for the treatment of patients with type 2 diabetes mellitus.” PMID 23512637 ↗ May 2013 “Empagliflozin is an effective treatment for heart failure with preserved ejection fraction (HFpEF), but its definite mechanism of action is unclear.” PMID 40281528 ↗ Apr 2025 “In this study, patients received standard clinical doses (e.g., dapagliflozin 5-10 mg once daily or empagliflozin 10-25 mg once daily) for 6 months.” NCT07539584 ↗ “METHODS: Of 498 patients randomized to empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily for 24 weeks in the EMPA-REG PIO™ study” PMID 26138864 ↗ Jun 2015 “The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study.” PMID 33306161 ↗ Dec 2020 “Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.” PMID 35472672 ↗ Jun 2022 “Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure.” NCT07172971 ↗ “Concurrent with starting the five-hour infusion, T1DM participants in the Eu-Ins study will receive an SGLT2i dose (empagliflozin 25 mg).” NCT06609356 ↗ “Empagliflozin is an SGLT2i that aids in blood glucose reduction through the urination of excess glucose in the context of hyperglycemia.” NCT06753994 ↗ “The choice of AOMs considered may include metformin, topiramate, liraglutide, dulaglutide, semaglutide, tirzepatide, and empagliflozin.” NCT07027969 ↗ “Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development as an oral antidiabetic treatment.” PMID 23617452 ↗ Apr 2013 “Efficacy of Vildagliptin, Liraglutide and Empagliflozin in the Management of Fatty Liver Disease Among Patients With Type 2 Diabetes” NCT05041673 ↗ “two fixed-dose combinations (FDCs) of sitagliptin 100 mg with empagliflozin 10 mg (DW1026C1) or empagliflozin 25 mg (DW1026C2)” PMID 41883295 ↗ Mar 2026 “receive combination of metformin, pioglitazone, and an SGLT2 inhibitor (empagliflozin or dapagliflozin or canagliflozin)” NCT04419337 ↗ “adding dapagliflozin or empagliflozin 10 mg once daily to post-TxC routine compared with no intervention for 6-8 months.” NCT06147271 ↗ “Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin after an overnight fast” NCT05823870 ↗ “BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).” NCT01131676 ↗ “Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition” NCT05823883 ↗ “Empagliflozin will be started at 10 mg daily per oral administration, and augmented to 25 mg/per day if required” NCT04196231 ↗ “Semaglutide 0.25 mg once weekly (qw) + Empagliflozin 10 mg once daily (qd) + Pioglitazone 15 mg once daily (qd)” NCT06946628 ↗ “A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.” NCT06143566 ↗ “The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills” NCT06124924 ↗ “Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.” PMID 27692976 ↗ Sep 2016 “SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD” NCT07391267 ↗ “Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment” NCT01164501 ↗ “For the SGLT2 inhibitor group, empagliflozin 10mg or dapagliflozin 10mg once daily is administered.” NCT05975528 ↗ “the second group will receive an SGLT2 inhibitor (dapagliflozin or empagliflozin 10 mg once daily)” NCT07563647 ↗ “Empagliflozin 10mg tablet, Valsartan+Sacubitril 100-200-400 mg tablet, Finerenone 20-40 mg tablet” NCT06655480 ↗ “Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus” NCT01193218 ↗ “Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.” NCT05636774 ↗ “empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage” NCT05278962 ↗ “Polypill formulation consisting of metoprolol succinate, empagliflozin, and spironolactone.” NCT04633005 ↗ “group-2 will receive SGLT2i (empagliflozin 10 mg once a day) and ARBs (losartan 50 mg/day)” NCT07586371 ↗ “Group empagliflozin: stander treatment of type two diabetes mellitus plus empagliflozin” NCT06117137 ↗ “the SGLT2 inhibitor (dapagliflozin 10 mg once daily or empagliflozin 10 mg once daily)” NCT07572032 ↗ “Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg” NCT04869800 ↗ “Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function” NCT01111318 ↗ “Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers” NCT01111331 ↗ “Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension” NCT00881530 ↗ “SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily” NCT02041234 ↗ “Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus” NCT01370005 ↗ “Withdrawal of spironolactone or eplerenone and dapagliflozin or empagliflozin” NCT06091475 ↗ “Dapagliflozin 10 mg once daily (QD) or Empagliflozin 10 mg once daily (QD)” NCT07105917 ↗ “Drug: EMPAGLIFLOZIN Empagliflozin 25 mg 1 coated tablet, once a day.” NCT05144360 ↗ “Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin” NCT01304329 ↗ “SGLT2 inhibitor: dapagliflozin or empagliflozin at 10 mg per day” NCT07513883 ↗ “Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally” NCT05610956 ↗ “One tablet each of Teneligliptin and Empagliflozin High by oral” NCT06339788 ↗ “Once daily treatment with oral empagliflozin (Jardiance) 10 mg” NCT03433248 ↗ “dapagliflozin","empagliflozin","canagliflozin","ertugliflozin” NCT04505774 ↗ “Empagliflozin 10 mg oral tablets Once Daily for 3-6 months” NCT05417880 ↗ “Tirzepatide, empagliflozin, and pioglitazone treatment.” NCT07635953 ↗ “an SGLT2 inhibitor (empagliflozin or dapagliflozin)” NCT06930092 ↗ “"Empagliflozin" will be added to a basal insulin.” NCT02846233 ↗ “subgroup 4A- addition of empagliflozin 10 mg/day” NCT03804411 ↗ “Either empagliflozin or dapagliflozin 10 mg/day” NCT05989503 ↗ “name and concentration of drug Empagliflozin 25” NCT07363707 ↗ “Empagliflozin, dapagliflozin, or canagliflozin” NCT05390892 ↗ “SGLT2i can be dapagliflozin or empagliflozin.” NCT07331220 ↗ “Empagliflozin 10mg once daily from discharge” NCT05013112 ↗ “Empagliflozin (SGLT-II inhibitor; 10 mg)” NCT04027023 ↗ “such as dapagliflozin and empagliflozin” NCT07335900 ↗ “Lobeglitazone, Empagliflozin, Metformin” NCT06492655 ↗ “empagliflozin (10-25mg daily)” NCT02528019 ↗ “empagliflozin (Jardiance®)” NCT07325435 ↗ “Empagliflozin (BI 10773)” NCT01248364 ↗ “Empagliflozin (BI 10773)” NCT01242176 ↗ “Empagliflozin (BI 10773)” NCT01211197 ↗ “empagliflozin (10mg qd)” NCT07482020 ↗ “Empagliflozin” NCT02041234 ↗ “Empagliflozin” NCT06753994 ↗ “empagliflozin” NCT04662723 ↗ |
| Known as | BI 10773 | “Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers” NCT01284621 ↗46“24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension” NCT02182830 ↗ “Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food” NCT01189201 ↗ “Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects” NCT01195675 ↗ “Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment” NCT01164501 ↗ “Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes” NCT01167881 ↗ “Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus” NCT01193218 ↗ “Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers” NCT01111331 ↗ “Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension” NCT00881530 ↗ “A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773)” NCT01649297 ↗ “Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus” NCT01370005 ↗ “Drug-drug Interaction of Empagliflozin (BI 10773) and Simvastatin” NCT01304329 ↗ “Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon” NCT01328184 ↗ “Empagliflozin (BI 10773), Film-coated tablet, single dose” NCT01634100 ↗ “Empagliflozin (BI 10773)” NCT01211197 ↗ “Empagliflozin (BI 10773)” NCT01242176 ↗ “Empagliflozin (BI 10773)” NCT01248364 ↗ “Empagliflozin (BI 10773)” NCT06851962 ↗ |
| Known as | BI 10773 XX | “Empagliflozin (BI 10773 XX)” NCT01242176 ↗ |
| Known as | EMPA | “This double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov NCT02453555) evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg as add-on to...” PMID 29766636 ↗ Jun 201812“Newly diagnosed patients with type 2 diabetes (T2D) will be randomly allocated to once daily 25 mg empagliflozin (EMPA) or placebo for 24 weeks with a computer-generated random...” NCT02637973 ↗ “evaluated the efficacy and safety of empagliflozin (Empa) 10 or 25 mg and linagliptin (Lina) 5 mg fixed-dose combinations (FDCs) in Japanese patients with type 2 diabetes...” PMID 30091172 ↗ Sep 2018 “This study aimed to investigate the complementary effects of combination therapy with pioglitazone (PIO) and empagliflozin (EMPA) on MASLD in individuals with type 2 diabetes.” PMID 40336058 ↗ May 2025 “We hypothesized that empaglifozin (EMPA) could modulate ectopic fat stores and myocardial energetics in high-fat-high-sucrose (HFHS) diet mice and in type 2 diabetics (T2D).” PMID 33648515 ↗ Mar 2021 “Empagliflozin (Empa) belongs to a novel class of anti-hyperglycemic drugs which was approved by the FDA on August 1, 2014.” NCT06641128 ↗ “adults with T1D received 5 mg/day empagliflozin (EMPA) or no drug (NOEMPA) as adjunct to insulin therapy.” PMID 35255229 ↗ Mar 2022 “Drug: Empagliflozin (EMPA)” NCT07591077 ↗ “Empagliflozin (EMPA)” NCT07692256 ↗ “Empagliflozin (EMPA)” NCT07472920 ↗ “Empagliflozin (EMPA)” NCT06729996 ↗ “Empagliflozin (EMPA)” NCT07146880 ↗ “Empagliflozin (Empa)” NCT05138575 ↗ |
| Known as | Empagliflozin, Jardiance | “empagliflozin (Jardiance®)” NCT07325435 ↗1“Empagliflozin, Jardiance” NCT05129722 ↗ |
| Known as | Jardiance | “A placebo-controlled randomized trial of our group has shown that a short-term, i.e. a 4-days administration of the SGLT2 inhibitor empagliflozin (Jardiance)® in addition to...” NCT04447911 ↗26“Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2.” NCT02729766 ↗ “All participants received a single oral dose of empagliflozin (JARDIANCE ®; 10 mg film coated tablet) in the evening, and after a seven-day washout period, the morning.” PMID 34123370 ↗ Apr 2021 “Empagliflozin, which is sold under the name of Jardiance, is FDA approved for patients 10 years of age and older to improve glycemic control in type 2 diabetes.” NCT07228195 ↗ “Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2).” NCT05174507 ↗ “This new drug (Jardiance®, substance: empagliflozin) is currently approved in Switzerland for the treatment of patients with diabetes.” NCT04911660 ↗ “A Bioequivalence Study of Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg, in Healthy Thai Volunteers Under Fasting Condition” NCT06232239 ↗ “The preferred prescription will be empagliflozin (Jardiance) 10mg daily with a 90-day fill and no refills” NCT06124924 ↗ “Empagliflozin (Jardiance™) is licensed in the UK for use in type 2 diabetes management.” NCT02798744 ↗ “10 mg and 25 mg empagliflozin tablets (Jardiance) can be prescribed in some countries.” NCT06083675 ↗ “Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg.” NCT05036317 ↗ “Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-inhibitor” NCT02874807 ↗ “Empagliflozin (Jardiance®), 10 mg tablet taken orally once daily for 4 weeks.” NCT07055282 ↗ “Empagliflozin, (Jardiance®) in patients with GSD Ib” NCT05960617 ↗ “Drug: Empagliflozin 10 MG Oral Tablet [Jardiance]” NCT07038356 ↗ “Empagliflozin Oral Tablet [Jardiance]” NCT03912909 ↗ “Empagliflozin 10 MG [Jardiance]” NCT03078101 ↗ “empagliflozin (Jardiance) 25 mg” NCT03852901 ↗ “Empagliflozin 10 MG [Jardiance]” NCT07169981 ↗ “Empagliflozin 10 MG [Jardiance]” NCT06989723 ↗ “Empagliflozin (Jardiance®)” NCT03437330 ↗ |
| Action | Inhibit | “a sodium glucose cotransporter 2 inhibitor” PMID 23940010 ↗ Aug 2013 |
| Modality | Small molecule | “Whether the SGLT2 inhibitor empagliflozin would improve or worsen frailty status when given to HFpEF patients is also not known.” PMID 38158636 ↗ Dec 2023 |
| Route | Oral | “Three Oral Doses of BI 10773” NCT00558571 ↗ |